Status:
COMPLETED
Aripiprazole Treatment of Prodromal Patients
Lead Sponsor:
Yale University
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Schizophrenia
Psychosis
Eligibility:
All Genders
13-40 years
Phase:
PHASE2
PHASE3
Brief Summary
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
Detailed Description
This is an 8 week trial with extension for responders out to one year. All patients receive active medication; there is no placebo. Patients must meet criteria for the schizophrenia prodrome according...
Eligibility Criteria
Inclusion
- age 13 to 40 meet criteria for the prodrome for schizophrenia
Exclusion
- history of psychosis
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00237874
Start Date
February 1 2004
End Date
February 1 2007
Last Update
June 6 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Living
Hartford, Connecticut, United States, 06106
2
Yale School of Medicine
New Haven, Connecticut, United States, 06512